Bioactive Technologies For Bone Replacement
This article was originally published in Start Up
Executive Summary
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. This article is reprinted from the April 2010 issue of Medtech Insight (Also see "Bioactive Technologies for Bone Replacement" - Medtech Insight, 1 Apr, 2010.).
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover FDA panels' thumbs-down rulings on Styker's OP1-Putty and Therox's SuperSaturated Oxygen Therapy System, a potential curb on payments for negative pressure wound therapy pumps, CMS' review of carotid stenting coverage, and Abbott Vascular move into the second phase of its ABSORB trial for its drug-eluting stent.
Advanced Wound Care: Untapped Opportunities
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
Cartilage Regeneration: Solving The Unsolvable?
CartiHeal's simple, cell-free construct may offer a potential solution to one of the greatest unsolved problems in musculoskeletal surgery – cartilage regeneration. An interview with Nir Altschuler, founder and CEO of the Israeli start-up.